首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

2126438

診斷CRO服務市場：策略性洞察與預測（2026-2035年）

Diagnostic CRO Services Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月12日 | 出版商:

Knowledge Sourcing Intelligence | 英文 171 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計診斷 CRO 服務市場將以 10.1% 的複合年成長率成長，從 2026 年的 87.6 億美元成長到 2035 年的 207.8 億美元。

全球診斷CRO服務市場正經歷顯著成長，這主要得益於診斷開發日益複雜化以及精準醫療的擴展。診斷CRO服務提供專業能力，使製藥公司、生技公司、診斷試劑製造商和醫療設備開發商能夠有效率地進行診斷產品的臨床開發。現代診斷開發已超越了簡單的實驗室檢驗，涵蓋了生物標記合格評估、多中心臨床試驗、監管策略、品管、統計分析和商業化規劃等諸多方面。先進的分子診斷需要多學科的科學專業知識和全球協調的臨床運營，這往往會導致內部開發團隊面臨基礎設施的限制。外包服務使企業能夠利用專業能力，同時提高營運柔軟性和開發效率。隨著伴隨診斷和精準醫療在腫瘤學、神經病學、感染疾病、心血管疾病和罕見疾病等領域的不斷擴展，市場需求也不斷成長。現代診斷技術對分析檢驗、臨床證據產生和監管文件編制的要求日益複雜，遠遠超出了傳統臨床研究的能力範圍。診斷 CRO 服務的策略重要性不僅限於臨床試驗，還包括生物標記主導的藥物開發、伴隨診斷的商業化、精準醫療研究以及上市後證據產生。

市場促進因素

對伴隨診斷和精準醫療的需求日益成長

伴隨診斷在確定患者合格標靶治療方面發揮日益重要的作用，使得臨床診斷研究成為藥物研發的關鍵環節。製藥公司需要整合實驗室、臨床和法規方面的專業知識，才能在開發候選治療藥物的同時開發伴隨診斷，這使得與專業合約研究組織 (CRO) 的合作需求日益成長。企業內部的研發能力往往難以在維持法規品質一致性的同時管理多個生物標記專案。診斷 CRO 正在擴展其整合的臨床開發平台，將生物標記檢驗、患者招募、檢測和法規諮詢整合到統一的專案中。這種轉變正在推動對專業診斷 CRO 服務的長期需求。

診斷和臨床研發外包增加

診斷試劑的研發日益需要涵蓋分子生物學、臨床實務、生物統計學、法規事務和實驗室科學等跨領域領域的專業知識。製藥和生技公司不斷擴大外包業務，因為外部合作夥伴能夠提供專業的基礎設施，而無需巨額資本投資。因此，內部資源的限制促使企業與擁有成熟研究和營運能力的合約研究組織（CRO）建立策略夥伴關係。診斷CRO正在增加對集中式檢測設施、數位化臨床試驗技術和全球營運網路的投資，以提高檢測效率並縮短產品上市時間。這些趨勢正在推動整個診斷產業對外包業務的持續需求。

分子診斷和生物標記檢驗。

現代診斷產品擴大將基因組學、蛋白質組學、數位病理學、生物資訊學和人工智慧整合到高度複雜的檢測平台中。隨著監管機構要求在商業化之前進行全面的分析驗證、臨床效能評估和軟體檢驗，產品開發的複雜性不斷增加。診斷產品開發公司正與專業的合約研究組織 (CRO) 合作，這些 CRO 可提供檢查室驗證、統計分析、臨床營運和監管策略方面的專業知識。 CRO 不斷提升其科研能力，以提高產品開發質量，同時支援日益複雜的分子診斷專案。這種技術變革正在推動外包診斷研究服務的持續擴張。

生物標記主導的臨床開發擴展

生物標記在整體藥物研發過程中，對受試者招募、治療選擇、臨床試驗分層和治療監測的影響日益增強。隨著標靶治療需要經臨床檢驗的生物標記來準確識別對治療有反應的患者群體，精準醫療也在不斷發展。因此，診斷開發不再是獨立的下游流程，而是藥物研發不可或缺的一部分。合約研究組織（CRO）正在建立整合生物標記發現、中心檢查室檢測、臨床運營和法規諮詢的綜合開發項目，從而加強治療創新和診斷創新之間的聯繫。這種整合式開發模式持續推動市場成長。

市場限制因素

國際市場監管的日益複雜化持續延長診斷產品的臨床開發週期和文件編制要求。分子診斷、伴隨診斷和生物標記檢驗所涉及的高度科學複雜性需要專業的知識和技能，而快速擴大規模仍面臨挑戰。對專有生物標記數據、病患資訊和智慧財產權的保護，持續影響製藥和生技公司在外包方面的決策。

按服務類型
- 臨床試驗管理
- 生物標記的開發和檢驗
- 中央檢驗服務
- 醫藥和臨床諮詢
- 數據管理和生物統計學
- 醫學寫作與藥物警戒
- 其他CRO服務
按診斷類型
- 分子診斷
- 伴隨診斷
- 免疫診斷
- 基於次世代定序（NGS）的診斷
- 即時診斷
- 數位病理診斷
- 其他診斷類型
最終用戶
- 製藥和生物技術公司
- 診斷設備製造商
- 醫療設備製造商
- 學術研究機構

第10章診斷CRO服務市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：診斷CRO服務市場：國別分析

美國
加拿大
德國
英國
法國
義大利
中國
日本
韓國
印度
澳洲
巴西
沙烏地阿拉伯

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
服務啟動

第13章：公司簡介

IQVIA Inc.
ICON plc
Labcorp Drug Development
Charles River Laboratories International, Inc.
Medpace Holdings, Inc.
Precision for Medicine
Eurofins Scientific SE
Q2 Solutions（IQVIA）
Frontage Laboratories, Inc.
WuXi AppTec Co., Ltd.
BioAgilytix Labs, LLC
SGS SA
NAMSA
Veranex, Inc.
Avania

第14章：診斷CRO服務市場：商業預測分析

按診斷類型進行的預測
- 伴隨診斷
- 分子診斷
- 免疫診斷
- 基於次世代定序（NGS）的診斷
最終用戶的預測
- 製藥和生物技術公司
- 診斷設備製造商
- 醫療設備製造商

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009156

The Diagnostic CRO Services Market is forecast to grow at a CAGR of 10.1%, reaching USD 20.78 billion in 2035 from USD 8.76 billion in 2026.

The global diagnostic CRO services market is experiencing significant growth, driven by the increasing complexity of diagnostic development and the expansion of precision medicine. Diagnostic CRO services provide specialized capabilities that enable pharmaceutical companies, biotechnology organizations, diagnostic manufacturers, and medical device developers to conduct efficient clinical development of diagnostic products. Modern diagnostic development extends beyond laboratory validation by incorporating biomarker qualification, multicenter clinical studies, regulatory strategy, quality management, statistical analysis, and commercialization planning. Internal development teams frequently encounter infrastructure limitations because advanced molecular diagnostics require multidisciplinary scientific expertise and globally coordinated clinical operations. Outsourcing therefore enables organizations to access specialized capabilities while improving operational flexibility and development efficiency. Demand is increasing because companion diagnostics and precision medicine continue expanding across oncology, neurology, infectious diseases, cardiovascular disorders, and rare diseases. Modern diagnostic technologies require increasingly sophisticated analytical validation, clinical evidence generation, and regulatory documentation that extend beyond conventional clinical research capabilities. The strategic importance of diagnostic CRO services extends beyond clinical trials into biomarker-driven drug development, companion diagnostic commercialization, precision medicine research, and post-market evidence generation.

Market Drivers

Rising Demand for Companion Diagnostics and Precision Medicine

Companion diagnostics increasingly determine patient eligibility for targeted therapies, making clinical diagnostic research an essential component of pharmaceutical development. Demand is shifting toward specialized CRO partnerships because pharmaceutical companies require coordinated laboratory, clinical, and regulatory expertise to develop companion diagnostics alongside therapeutic candidates. Internal development capabilities frequently struggle to manage multiple biomarker programs while maintaining consistent regulatory quality. Diagnostic CROs are expanding integrated clinical development platforms that combine biomarker validation, patient recruitment, laboratory testing, and regulatory consulting within unified programs. This transition strengthens long-term demand for specialized diagnostic CRO services.

Increasing Outsourcing of Diagnostic Clinical Development

Diagnostic development increasingly requires multidisciplinary expertise spanning molecular biology, clinical operations, biostatistics, regulatory affairs, and laboratory sciences. Pharmaceutical and biotechnology companies continue expanding outsourcing because external partners provide specialized infrastructure without requiring significant capital investment. Internal resource limitations therefore encourage strategic collaboration with CROs possessing established scientific and operational capabilities. Diagnostic CROs are increasing investment in centralized laboratories, digital clinical trial technologies, and global operational networks that improve study efficiency while reducing commercialization timelines. These developments reinforce sustained outsourcing demand across the diagnostic industry.

Growing Complexity of Molecular Diagnostics and Biomarker Validation

Modern diagnostic products increasingly integrate genomics, proteomics, digital pathology, bioinformatics, and artificial intelligence into highly sophisticated testing platforms. Development complexity continues increasing because regulatory agencies require comprehensive analytical validation, clinical performance evaluation, and software verification before commercialization. Diagnostic developers are partnering with specialized CROs that provide expertise across laboratory validation, statistical analysis, clinical operations, and regulatory strategy. CROs continue strengthening scientific capabilities that improve development quality while supporting increasingly complex molecular diagnostic programs. This technological evolution supports continued expansion of outsourced diagnostic research services.

Expansion of Biomarker-Driven Clinical Development

Biomarkers increasingly influence patient recruitment, treatment selection, clinical trial stratification, and therapeutic monitoring throughout pharmaceutical development. Precision medicine continues expanding because targeted therapies require clinically validated biomarkers that accurately identify responsive patient populations. Diagnostic development therefore becomes an integral component of drug development rather than a separate downstream activity. CROs are integrating biomarker discovery, central laboratory testing, clinical operations, and regulatory consulting into comprehensive development programs that improve coordination between therapeutic and diagnostic innovation. This integrated development model continues strengthening market growth.

Market Restraints

Increasing regulatory complexity across international markets continues extending diagnostic clinical development timelines and documentation requirements. High scientific complexity associated with molecular diagnostics, companion diagnostics, and biomarker validation requires specialized expertise that remains difficult to scale rapidly. Protection of proprietary biomarker data, patient information, and intellectual property continues influencing outsourcing decisions among pharmaceutical and biotechnology companies.

Technology and Segment Insights

By Service Type

Clinical Trial Management, Biomarker Development & Validation, Central Laboratory Services, Regulatory Affairs & Clinical Consulting, Data Management & Biostatistics, Medical Writing & Pharmacovigilance, and Other CRO Services collectively define the diagnostic CRO service landscape. Clinical trial management coordinates operational execution, while biomarker validation and central laboratory services generate scientific evidence supporting regulatory submissions. Demand is increasing for integrated service models because diagnostic developers seek outsourcing partners capable of managing clinical, laboratory, and regulatory activities within a single development program. Data management, statistical analysis, and medical writing continue becoming more important as diagnostic studies generate increasingly complex clinical and molecular datasets.

By Diagnostic Type

Molecular Diagnostics, Companion Diagnostics, Immunodiagnostics, Next-Generation Sequencing (NGS)-Based Diagnostics, Point-of-Care Diagnostics, Digital Pathology Diagnostics, and Other Diagnostic Types represent the principal categories requiring specialized CRO support. Companion diagnostics continue generating substantial demand because targeted therapeutics require coordinated clinical validation alongside pharmaceutical development. Molecular diagnostics and NGS-based assays increasingly require sophisticated laboratory infrastructure, bioinformatics expertise, and regulatory strategy due to growing analytical complexity. Digital pathology and point-of-care diagnostics are also increasing outsourcing demand as developers pursue accelerated commercialization and international regulatory approvals.

By End User

Pharmaceutical & Biotechnology Companies, Diagnostic Manufacturers, Medical Device Companies, and Academic & Research Institutes each represent important sources of outsourcing demand. Pharmaceutical companies increasingly rely on CROs because biomarker-driven clinical development requires coordinated laboratory, clinical, and regulatory expertise throughout therapeutic development. Diagnostic manufacturers continue outsourcing specialized scientific services to improve commercialization efficiency while reducing internal infrastructure investment. Medical device companies are expanding partnerships as software-enabled diagnostics and integrated testing platforms become increasingly sophisticated. Academic institutions continue collaborating with CROs to translate early-stage biomarker discoveries into clinically validated diagnostic products.

Competitive and Strategic Outlook

The competitive landscape features major clinical research and laboratory service organizations. IQVIA Inc. distinguishes itself through its ability to integrate clinical research, real-world evidence, advanced analytics, and regulatory expertise. ICON plc differentiates itself through its integrated clinical research, laboratory sciences, and regulatory consulting capabilities supporting the complete lifecycle of diagnostic development. Labcorp Drug Development distinguishes itself through its extensive global central laboratory network and clinical development expertise. Charles River Laboratories International, Inc. distinguishes itself through its translational research, biomarker discovery, and preclinical development expertise. Medpace Holdings, Inc. maintains a strong position through its specialized therapeutic focus and integrated clinical research model.
Strategic developments include increasing integration of artificial intelligence and decentralized clinical trial capabilities, expansion of companion diagnostic clinical programs, and growth of global regulatory and clinical consulting. Companies are forming partnerships to strengthen scientific, clinical, and regulatory capabilities. Service expansions focus on centralized laboratories, digital trial technologies, and advanced analytics. Companies that successfully integrate scientific expertise, clinical operations, regulatory knowledge, and global infrastructure are expected to lead the market.

Conclusion

The diagnostic CRO services market is poised for significant growth, driven by the rising demand for companion diagnostics, increasing diagnostic complexity, and expansion of biomarker-driven clinical development. The evolution toward integrated, full-service clinical development partnerships supporting the entire diagnostic lifecycle is reshaping the market. Companies that successfully deliver comprehensive scientific, clinical, regulatory, and commercialization expertise are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding precision medicine adoption will further accelerate development throughout the forecast period.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Diagnostic CRO Services Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Diagnostic Clinical Development Landscape
3.8 Companion Diagnostics Development Trends
3.9 Biomarker Development and Validation Landscape
3.10 Outsourcing Trends in Diagnostic Clinical Research

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Technologies
6.2 Service Innovation
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 AI Integration in Clinical Trial Management
6.6 Digital Health Integration

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Diagnostic CRO Services Market Landscape Analysis

8.1 Analysis by Service Type
8.2 Analysis by Clinical Development Phase
8.3 Analysis by Diagnostic Type
8.4 Analysis by Therapeutic Area
8.5 Analysis by Trial Model

9. Diagnostic CRO Services Market Segment Analysis (2021-2035)

9.1 By Service Type
- 9.1.1 Clinical Trial Management
- 9.1.2 Biomarker Development & Validation
- 9.1.3 Central Laboratory Services
- 9.1.4 Regulatory Affairs & Clinical Consulting
- 9.1.5 Data Management & Biostatistics
- 9.1.6 Medical Writing & Pharmacovigilance
- 9.1.7 Other CRO Services
9.2 By Diagnostic Type
- 9.2.1 Molecular Diagnostics
- 9.2.2 Companion Diagnostics
- 9.2.3 Immunodiagnostics
- 9.2.4 Next-Generation Sequencing (NGS)-Based Diagnostics
- 9.2.5 Point-of-Care Diagnostics
- 9.2.6 Digital Pathology Diagnostics
- 9.2.7 Other Diagnostic Types
9.3 By End User
- 9.3.1 Pharmaceutical & Biotechnology Companies
- 9.3.2 Diagnostic Manufacturers
- 9.3.3 Medical Device Companies
- 9.3.4 Academic & Research Institutes

10. Diagnostic CRO Services Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Diagnostic CRO Services Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 China
11.8 Japan
11.9 South Korea
11.10 India
11.11 Australia
11.12 Brazil
11.13 Saudi Arabia

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Service Launches

13. Company Profiles

13.1 IQVIA Inc.
13.2 ICON plc
13.3 Labcorp Drug Development
13.4 Charles River Laboratories International, Inc.
13.5 Medpace Holdings, Inc.
13.6 Precision for Medicine
13.7 Eurofins Scientific SE
13.8 Q2 Solutions (IQVIA)
13.9 Frontage Laboratories, Inc.
13.10 WuXi AppTec Co., Ltd.
13.11 BioAgilytix Labs, LLC
13.12 SGS SA
13.13 NAMSA
13.14 Veranex, Inc.
13.15 Avania

14. Diagnostic CRO Services Market Commercial Forecast Analysis

14.1 Forecast by Service Type
- 14.1.1 Clinical Trial Management
- 14.1.2 Biomarker Development & Validation
- 14.1.3 Central Laboratory Services
- 14.1.4 Regulatory Affairs & Clinical Consulting
14.2 Forecast by Diagnostic Type
- 14.2.1 Companion Diagnostics
- 14.2.2 Molecular Diagnostics
- 14.2.3 Immunodiagnostics
- 14.2.4 Next-Generation Sequencing (NGS)-Based Diagnostics
14.3 Forecast by End User
- 14.3.1 Pharmaceutical & Biotechnology Companies
- 14.3.2 Diagnostic Manufacturers
- 14.3.3 Medical Device Companies